サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1418351

ダプトマイシン市場レポート：2030年までの動向、予測、競合分析

Daptomycin Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日: | 発行: Lucintel | ページ情報: 英文 150 - page report | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

ダプトマイシン市場レポート：2030年までの動向、予測、競合分析
出版日: 2024年01月29日
発行: Lucintel
ページ情報: 英文 150 - page report
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

ダプトマイシンの動向と予測

世界のダプトマイシン市場は、2024年から2030年にかけてCAGR 4.5％で成長すると予測されます。この市場の主な促進要因は、皮膚および皮膚組織感染症に罹患する人口の増加と抗菌剤としての用途の拡大、および敗血症などの血流感染症の増加です。ダプトマイシンの世界市場は、300mgおよび500mg市場に機会があり、将来性が期待されます。

ダプトマイシン市場の洞察

Lucintel社は、研究開発イニシアチブの活発化により、予測期間中は複雑性皮膚組織感染症がより大きなセグメントであり続けると予測しています。

この市場において、500mgはその有効性と安定性により引き続き大きなセグメントとなると思われます。

北米は、いくつかの政府イニシアチブの高まりにより、予測期間中も最大の市場規模を維持するでしょう。

よくある質問

Q1.市場の成長予測は？

A1.世界のダプトマイシン市場は、2024年から2030年にかけてCAGR 4.5%で成長すると予想されています。

Q2.市場の成長に影響を与える主な促進要因は？

A2.この市場の主な促進要因は、皮膚および皮膚組織感染症に罹患する人口の増加と抗菌剤としての用途の拡大、および敗血症などの血流感染症の増加です。

Q3.市場の主要セグメントは？

A3.ダプトマイシン市場の将来性は、300mgおよび500mg市場に機会があることから有望です。

Q4.市場の主要企業は？

A4.ダプトマイシンの主要企業は以下の通り。

  • Teva Pharmaceuticals Industries
  • Merck
  • Cipla
  • Pfizer
  • BE Pharmaceuticals
  • Reddy'S Laboratories
  • Mylan
  • Fresenius Kabi
  • Nichi-Iko Pharmaceutical
  • Novo Holdings

Q5.今後、最大となる市場セグメントは？

A5.Lucintel社は、研究開発イニシアチブの高まりにより、予測期間中、複雑性皮膚組織感染症がより大きなセグメントであり続けると予測しています。

Q6.市場において、今後5年間に最大になると予想される地域は？

A6.北米は、いくつかの政府イニシアチブの高まりにより、予測期間中も最大規模を維持します。

Q7.レポートのカスタマイズは可能？

A7.はい、Lucintelは追加費用なしで10％のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界のダプトマイシン市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界のダプトマイシン市場動向（2018-2023）と予測（2024-2030）
  • 適応症別の世界のダプトマイシン市場
    • 複雑な皮膚組織感染症
    • 菌血症
  • 年齢層別の世界のダプトマイシン市場
    • 小児
    • 大人
  • 強さ別の世界のダプトマイシン市場
    • 300mg
    • 500mg

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界のダプトマイシン市場
  • 北米のダプトマイシン市場
  • 欧州のダプトマイシン市場
  • アジア太平洋のダプトマイシン市場
  • その他地域のダプトマイシン市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • 適応症別の世界のダプトマイシン市場の成長機会
    • 年齢層別の世界のダプトマイシン市場の成長機会
    • 強み別の世界のダプトマイシン市場の成長機会
    • 地域別の世界のダプトマイシン市場の成長機会
  • 世界のダプトマイシン市場の新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界のダプトマイシン市場の能力拡大
    • 世界のダプトマイシン市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Teva Pharmaceuticals Industries
  • Merck
  • Cipla
  • Pfizer
  • BE Pharmaceuticals
  • Reddy's Laboratories
  • Mylan
  • Fresenius Kabi
  • Nichi-Iko Pharmaceutical
  • Novo Holdings
目次

Daptomycin Trends and Forecast

The future of the global daptomycin market looks promising with opportunities in the 300mg and 500mg markets. The global daptomycin market is expected to grow with a CAGR of 4.5% from 2024 to 2030. The major drivers for this market are increasing population affected by skin and skin structure infections and expanding application as an antibacterial agent, and increasing bloodstream infections, such as sepsis.

A more than 150-page report is developed to help in your business decisions.

Daptomycin by Segment

The study includes a forecast for the global daptomycin by indication, age group , strength, and region.

Daptomycin Market by Indication [Shipment Analysis by Value from 2018 to 2030]:

  • Complicated Skin Structure Infections
  • Bacteremia

Daptomycin Market by Age Group [Shipment Analysis by Value from 2018 to 2030]:

  • Pediatric
  • Adult

Daptomycin Market by Strength [Shipment Analysis by Value from 2018 to 2030]:

  • 300mg
  • 500mg

Daptomycin Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Daptomycin Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies daptomycin companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the daptomycin companies profiled in this report include-

  • Teva Pharmaceuticals Industries
  • Merck
  • Cipla
  • Pfizer
  • BE Pharmaceuticals
  • Reddy'S Laboratories
  • Mylan
  • Fresenius Kabi
  • Nichi-Iko Pharmaceutical
  • Novo Holdings

Daptomycin Market Insights

Lucintel forecasts that complicated skin structure infections will remain the larger segment over the forecast period due to heightened research and development initiatives.

Within this market, 500mg will remain the larger segment due to its efficacy and stability.

North America will remain the largest over the forecast period due to growing several government initiatives.

Features of the Global Daptomycin Market

Market Size Estimates: Daptomycin market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Daptomycin market size by indication, age group , strength, and region in terms of value ($B).

Regional Analysis: Daptomycin market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different indication, age group , strength, and regions for the daptomycin market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the daptomycin market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for daptomycin market?

Answer: The global daptomycin market is expected to grow with a CAGR of 4.5% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the daptomycin market?

Answer: The major drivers for this market are increasing population affected by skin and skin structure infections and expanding application as an antibacterial agent, and increasing bloodstream infections, such as sepsis.

Q3. What are the major segments for daptomycin market?

Answer: The future of the daptomycin market looks promising with opportunities in the 300mg and 500mg markets.

Q4. Who are the key daptomycin market companies?

Answer: Some of the key daptomycin companies are as follows.

  • Teva Pharmaceuticals Industries
  • Merck
  • Cipla
  • Pfizer
  • BE Pharmaceuticals
  • Reddy'S Laboratories
  • Mylan
  • Fresenius Kabi
  • Nichi-Iko Pharmaceutical
  • Novo Holdings

Q5. Which daptomycin market segment will be the largest in future?

Answer: Lucintel forecasts that complicated skin structure infections will remain the larger segment over the forecast period due to heightened research and development initiatives.

Q6. In daptomycin market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest over the forecast period due to growing several government initiatives.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the daptomycin market by indication (complicated skin structure infections and bacteremia), age group (pediatric and adult), strength (300mg and 500mg), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Daptomycin Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Daptomycin Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Daptomycin Market by Indication
    • 3.3.1: Complicated skin structure infections
    • 3.3.2: Bacteremia
  • 3.4: Global Daptomycin Market by Age Group
    • 3.4.1: Pediatric
    • 3.4.2: Adult
  • 3.5: Global Daptomycin Market by Strength
    • 3.5.1: 300mg
    • 3.5.2: 500mg

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Daptomycin Market by Region
  • 4.2: North American Daptomycin Market
    • 4.2.2: North American Daptomycin Market by Strength: 300mg and 500mg
  • 4.3: European Daptomycin Market
    • 4.3.1: European Daptomycin Market by Indication: Complicated skin structure infections and Bacteremia
    • 4.3.2: European Daptomycin Market by Strength: 300mg and 500mg
  • 4.4: APAC Daptomycin Market
    • 4.4.1: APAC Daptomycin Market by Indication: Complicated skin structure infections and Bacteremia
    • 4.4.2: APAC Daptomycin Market by Strength: 300mg and 500mg
  • 4.5: ROW Daptomycin Market
    • 4.5.1: ROW Daptomycin Market by Indication: Complicated skin structure infections and Bacteremia
    • 4.5.2: ROW Daptomycin Market by Strength: 300mg and 500mg

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Daptomycin Market by Indication
    • 6.1.2: Growth Opportunities for the Global Daptomycin Market by Age Group
    • 6.1.3: Growth Opportunities for the Global Daptomycin Market by Strength
    • 6.1.4: Growth Opportunities for the Global Daptomycin Market by Region
  • 6.2: Emerging Trends in the Global Daptomycin Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Daptomycin Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Daptomycin Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Teva Pharmaceuticals Industries
  • 7.2: Merck
  • 7.3: Cipla
  • 7.4: Pfizer
  • 7.5: BE Pharmaceuticals
  • 7.6: Reddy's Laboratories
  • 7.7: Mylan
  • 7.8: Fresenius Kabi
  • 7.9: Nichi-Iko Pharmaceutical
  • 7.10: Novo Holdings